Not yet recruiting NCT07464028
Terazosin And Metabolic Energetics in Parkinson's Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Terazosin 5 MG, Placebo.
- Who it may be relevant to
- Registry conditions: Parkinson's Disease (PD). Basic parameters: 50 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)
Overview
This study investigates if Terazosin can improve metabolism in PD.
Interventions
- Drug Terazosin 5 MG
This drug increases glycolysis in Parkinson's disease. - Drug Placebo
Placebo control for Terazosin
Primary outcome measures
- ATP [Time frame: at 1.5 year]
Eligibility criteria
Parkinson's disease
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Basic science
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Schultz JL, Gander PE, Workman CD, Boles Ponto LL, Cross S, Nance CS, Groth CL, Taylor EB, Ernst SE, Xu J, Uc EY, Magnotta VA, Welsh MJ, Narayanan NS. A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults. J Parkinsons Dis. 2025 Nov;15(7):1253-1263. doi: 10.1177/1877718X251356503. Epub 2025 Aug 10. PMID 40785306
- Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, Consiglio A, Raya A, Polgreen PM, Narayanan NS, Yuan Y, Chen Z, Su W, Han Y, Zhao C, Gao L, Ji X, Welsh MJ, Liu L. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. J Clin Invest. 2019 Oct 1;129(10):4539-4549. doi: 10.1172/JCI129987. PMID 31524631
- Simmering JE, Welsh MJ, Liu L, Narayanan NS, Pottegard A. Association of Glycolysis-Enhancing alpha-1 Blockers With Risk of Developing Parkinson Disease. JAMA Neurol. 2021 Apr 1;78(4):407-413. doi: 10.1001/jamaneurol.2020.5157. PMID 33523098
- Schultz JL, Brinker AN, Xu J, Ernst SE, Tayyari F, Rauckhorst AJ, Liu L, Uc EY, Taylor EB, Simmering JE, Magnotta VA, Welsh MJ, Narayanan NS. A pilot to assess target engagement of terazosin in Parkinson's disease. Parkinsonism Relat Disord. 2022 Jan;94:79-83. doi: 10.1016/j.parkreldis.2021.11.022. Epub 2021 Nov 27. PMID 34894470
- Simmering JE, Welsh MJ, Schultz J, Narayanan NS. Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease. Mov Disord. 2022 Nov;37(11):2210-2216. doi: 10.1002/mds.29184. Epub 2022 Aug 22. PMID 36054705
- Weber MA, Sivakumar K, Tabakovic EE, Oya M, Aldridge GM, Zhang Q, Simmering JE, Narayanan NS. Glycolysis-enhancing alpha1-adrenergic antagonists modify cognitive symptoms related to Parkinson's disease. NPJ Parkinsons Dis. 2023 Mar 2;9(1):32. doi: 10.1038/s41531-023-00477-1. PMID 36864060
- Hart A, Aldridge G, Zhang Q, Narayanan NS, Simmering JE. Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men. Neurology. 2024 Jul 23;103(2):e209570. doi: 10.1212/WNL.0000000000209570. Epub 2024 Jun 19. PMID 38896813
Identifiers
NCT: NCT07464028 · 202510685